Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning.
Acelyrin, a struggling immunology biotech that’s faced several clinical setbacks ...
↧